|
1
|
Hsieh JJ, Purdue MP, Signoretti S, Swanton
C, Albiges L, Schmidinger M, Heng DY, Larkin J and Ficarra V: Renal
cell carcinoma. Nat Rev Dis Primers. 3:170092017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Capitanio U, Bensalah K, Bex A, Boorjian
SA, Bray F, Coleman J, Gore JL, Sun M, Wood C and Russo P:
Epidemiology of renal cell carcinoma. Eur Urol. 75:74–84. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ingels A, Campi R, Capitanio U, Amparore
D, Bertolo R, Carbonara U, Erdem S, Kara Ö, Klatte T, Kriegmair MC,
et al: Complementary roles of surgery and systemic treatment in
clear cell renal cell carcinoma. Nat Rev Urol. 19:391–418. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Prunty M, Bell S, Kutikov A and Bukavina
L: Review of robotic-assisted radical nephrectomy with inferior
vena cava thrombectomy in renal cell carcinoma. Curr Urol Rep Dec.
23:363–370. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rini BI, Campbell SC and Escudier B: Renal
cell carcinoma. Lancet. 373:1119–1132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ho TH, Serie DJ, Parasramka M, Cheville
JC, Bot BM, Tan W, Wang L, Joseph RW, Hilton T, Leibovich BC, et
al: Differential gene expression profiling of matched primary renal
cell carcinoma and metastases reveals upregulation of extracellular
matrix genes. Ann Oncol. 28:604–610. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pontes O, Oliveira-Pinto S, Baltazar F and
Costa M: Renal cell carcinoma therapy: Current and new drug
candidates. Drug Discov Today. 27:304–314. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gray RE and Harris GT: Renal cell
carcinoma: Diagnosis and management. Am Fam Physician. 99:179–184.
2019.PubMed/NCBI
|
|
9
|
Bigot P, Fardoun T, Bernhard JC, Xylinas
E, Berger J, Rouprêt M, Beauval JB, Lagabrielle S, Lebdai S, Ammi
M, et al: Neoadjuvant targeted molecular therapies in patients
undergoing nephrectomy and inferior vena cava thrombectomy: Is it
useful? World J Urol. 32:109–1014. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Martini A, Fallara G, Pellegrino F,
Cirulli GO, Larcher A, Necchi A, Montorsi F and Capitanio U:
Neoadjuvant and adjuvant immunotherapy in renal cell carcinoma.
World J Urol. 39:1369–1376. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Posadas EM and Figlin RA: Kidney cancer:
Progress and controversies in neoadjuvant therapy. Nat Rev Urol.
11:254–255. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Westerman ME, Shapiro DD, Wood CG and
Karam JA: Neoadjuvant Therapy for locally advanced renal cell
carcinoma. Urol Clin North Am Aug. 47:329–343. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bindayi A, Hamilton ZA, McDonald ML, Yim
K, Millard F, McKay RR, Campbell SC, Rini BI and Derweesh IH:
Neoadjuvant therapy for localized and locally advanced renal cell
carcinoma. Urol Oncol. 36:31–37. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liberati A, Altman DG, Tetzlaff J, Mulrow
C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J
and Moher D: The PRISMA statement for reporting systematic reviews
and meta-analyses of studies that evaluate healthcare
interventions: Explanation and elaboration. BMJ. 339:b27002009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hozo SP, Djulbegovic B and Hozo I:
Estimating the mean and variance from the median, range, and the
size of a sample. BMC Med Res Methodol. 5:132005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wan X, Wang W, Liu J and Tong T:
Estimating the sample mean and standard deviation from the sample
size, median, range and/or interquartile range. BMC Med Res
Methodol. 14:1352014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Higgins JP, Altman DG, Gotzsche PC, Jüni
P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, et
al: The Cochrane Collaboration's tool for assessing risk of bias in
randomised trials. BMJ. 343:d59282011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Stang A: Critical evaluation of the
Newcastle-Ottawa scale for the assessment of the quality of
nonrandomized studies in meta-analyses. Eur J Epidemiol.
25:603–605. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hatiboglu G, Hohenfellner M, Arslan A,
Hadaschik B, Teber D, Radtke JP, Hallscheidt P, Tolstov Y, Roth W,
Grüllich C, et al: Effective downsizing but enhanced intratumoral
heterogeneity following neoadjuvant sorafenib in patients with
non-metastatic renal cell carcinoma. Langenbecks Arch Surg.
402:637–644. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Voylenko O, Pikul M, Stakhovsky E,
Stakhovskyi O, Semko S, Kononenko OA and Vitruk I: Influence of
neoadjuvant targeted therapy on perioperative complication rate.
Eur Urol Open Sci. 19:e2382020. View Article : Google Scholar
|
|
21
|
Field CA, Cotta BH, Jimenez J, Lane BR,
Yim K, Lee HJ, Ryan ST, Hamilton ZA, Patel S, Wang S, et al:
Neoadjuvant sunitinib decreases inferior vena caval thrombus size
and is associated with improved oncologic outcomes: A multicenter
comparative analysis. Clin Genitourin Cancer. 17:e505–e512. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Semko S, Pikul M, Stakhovsky E, Voylenko
O, Stakhovskyi O, Vitruk I, Hrechko B and Kononenko O: Oncological
outcome of neoadjuvant target therapy in patients with localized
RCC. Eur Urol. 79:S7702021. View Article : Google Scholar
|
|
23
|
Tanaka Y, Hatakeyama S, Hosogoe S, Tanaka
T, Hamano I, Kusaka A, Iwamura H, Fujita N, Yamamoto H, Tobisawa Y,
et al: Presurgical axitinib therapy increases fibrotic reactions
within tumor thrombus in renal cell carcinoma with thrombus
extending to the inferior vena cava. Int J Clin Oncol. 23:134–141.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Okamura Y, Terakawa T, Sakamoto M, Bando
Y, Suzuki K, Hara T, Furukawa J, Harada K, Hinata N, Nakano Y and
Fujisawa M: Presurgical pazopanib improves surgical outcomes for
renal cell carcinoma with High-level IVC tumor thrombosis. In Vivo.
33:2013–2019. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
McDonald ML, Lane BR, Jimenez J, Lee HJ,
Yim K, Bindayi A, Hamilton ZA, Field CA, Bloch AS, Dey S, et al:
Renal functional outcome of partial nephrectomy for complex
R.E.N.A.L. score tumors with or without neoadjuvant sunitinib: A
multicenter analysis. Clin Genitourin Cancer. 16:e289–e295. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chapin BF, Delacroix SE Jr, Culp SH,
Nogueras Gonzalez GM, Tannir NM, Jonasch E, Tamboli P and Wood CG:
Safety of presurgical targeted therapy in the setting of metastatic
renal cell carcinoma. Eur Urol. 60:964–971. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Harshman LC, Yu RJ, Allen GI, Srinivas S,
Gill HS and Chung BI: Surgical outcomes and complications
associated with presurgical tyrosine kinase inhibition for advanced
renal cell carcinoma (RCC). Urol Oncol. 31:379–385. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Clavien PA, Barkun J, de Oliveira ML,
Vauthey JN, Dindo D, Schulick RD, de Santibañes E, Pekolj J,
Slankamenac K, Bassi C, et al: The Clavien-Dindo classification of
surgical complications: Five-year experience. Ann Surg.
250:187–196. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen K, Liu Z, Li Y, Zhao X, Wang G, Tian
X, Zhang H, Ma L and Zhang S: Prevention, incidence, and risk
factors of chyle leak after radical nephrectomy and thrombectomy.
Cancer Med. 13:e68582023. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Colomer R, Saura C, Sanchez-Rovira P,
Pascual T, Rubio IT, Burgués O, Marcos L, Rodríguez CA, Martín M
and Lluch A: Neoadjuvant management of early breast cancer: A
clinical and investigational position statement. Oncologist.
24:603–611. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Karam JA, Devine CE, Urbauer DL, Lozano M,
Maity T, Ahrar K, Tamboli P, Tannir NM and Wood CG: Phase 2 trial
of neoadjuvant axitinib in patients with locally advanced
nonmetastatic clear cell renal cell carcinoma. Eur Urol.
66:874–880. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bex A, Mulders P, Jewett M, Wagstaff J,
van Thienen JV, Blank CU, van Velthoven R, Del Pilar Laguna M, Wood
L, van Melick HHE, et al: Comparison of immediate vs deferred
cytoreductive nephrectomy in patients with synchronous metastatic
renal cell carcinoma receiving sunitinib: The SURTIMe randomized
clinical trial. JAMA Oncol. 5:164–170. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lane BR, Derweesh IH, Kim HL, O'Malley R,
Klink J, Ercole CE, Palazzi KL, Thomas AA, Rini BI and Campbell SC:
Presurgical sunitinib reduces tumor size and may facilitate partial
nephrectomy in patients with renal cell carcinoma. Urol Oncol.
33:112.e15–e21. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lebacle C, Bensalah K, Bernhard JC,
Albiges L, Laguerre B, Gross-Goupil M, Baumert H, Lang H, Tricard
T, Duclos B, et al: Evaluation of axitinib to downstage cT2a renal
tumours and allow partial nephrectomy: A phase II study. BJU.
123:804–810. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Margulis V, Matin SF, Tannir N, Tamboli P,
Swanson DA, Jonasch E and Wood CG: Surgical morbidity associated
with administration of targeted molecular therapies before
cytoreductive nephrectomy or resection of locally recurrent renal
cell carcinoma. J Urol. 180:94–98. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rini BI, Plimack ER, Takagi T, Elson P,
Wood LS, Dreicer R, Gilligan T, Garcia J, Zhang Z, Kaouk J, et al:
A Phase II study of pazopanib in patients with localized renal cell
carcinoma to optimize preservation of renal parenchyma. J Urol.
194:297–303. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Silberstein JL, Millard F, Mehrazin R,
Kopp R, Bazzi W, DiBlasio CJ, Patterson AL, Downs TM, Yunus F, Kane
CJ and Derweesh IH: Feasibility and efficacy of neoadjuvant
sunitinib before nephron-sparing surgery. BJU Int. 106:1270–1276.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Assi T, El Rassy E, Farhat F and Kattan J:
Overview on the role of preoperative therapy in the management of
kidney cancer. Clin Transl Oncol. 22:11–20. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cowey CL, Amin C, Pruthi RS, Wallen EM,
Nielsen ME, Grigson G, Watkins C, Nance KV, Crane J, Jalkut M, et
al: Neoadjuvant clinical trial with sorafenib for patients with
stage II or higher renal cell carcinoma. J Clin Oncol.
28:1502–1507. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hellenthal NJ, Underwood W, Penetrante R,
Litwin A, Zhang S, Wilding GE, Teh BT and Kim HL: Prospective
clinical trial of preoperative sunitinib in patients with renal
cell carcinoma. J Urol. 184:859–864. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Rini BI, Garcia J, Elson P, Wood L, Shah
S, Stephenson A, Salem M, Gong M, Fergany A, Rabets J, et al: The
effect of sunitinib on primary renal cell carcinoma and
facilitation of subsequent surgery. J Urol. 187:1548–1554. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Shuch B, Linehan WM and Bratslavsky G:
Repeat partial nephrectomy: Surgical, functional and oncological
outcomes. Curr Opin Urol. 21:368–375. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Voylenko OA, Stakhovsky OE, Vitruk IV,
Kononenko OA, Pikul MV, Semko SL and Stakhovsky EO: Efficacy of
neoadjuvant targeted therapy in treatment of patients with
localised clear-cell renal cell carcinoma. Adv Urol.
2021:66746372021. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Cost NG, Delacroix SE Jr, Sleeper JP,
Smith PJ, Youssef RF, Chapin BF, Karam JA, Culp S, Abel EJ,
Brugarolas J, et al: The impact of targeted molecular therapies on
the level of renal cell carcinoma vena caval tumor thrombus. Eur
Urol. 59:912–918. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Stewart GD, Welsh SJ, Ursprung S,
Gallagher FA, Jones JO, Shields J, Smith CG, Mitchell TJ, Warren
AY, Bex A, et al: A Phase II study of neoadjuvant axitinib for
reducing the extent of venous tumour thrombus in clear cell renal
cell cancer with venous invasion (NAXIVA). Br J Cancer.
127:1051–1060. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Schmidinger M, Arnold D, Szczylik C,
Wagstaff J and Ravaud A: Optimizing the use of sunitinib in
metastatic renal cell carcinoma: An update from clinical practice.
Cancer Invest. 28:856–864. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ljungberg B, Albiges L, Abu-Ghanem Y,
Bensalah K, Dabestani S, Fernández-Pello S, Giles RH, Hofmann F,
Hora M, Kuczyk MA, et al: European association of urology
guidelines on renal cell carcinoma: The 2019 update. Eur Urol.
75:799–810. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Dibajnia P, Cardenas LM and Lalani AA: The
emerging landscape of neo/adjuvant immunotherapy in renal cell
carcinoma. Hum Vaccin Immunother. 19:21782172023. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Labbate C, Hatogai K, Werntz R, Stadler
WM, Steinberg GD, Eggener S and Sweis RF: Complete response of
renal cell carcinoma vena cava tumor thrombus to neoadjuvant
immunotherapy. J Immunother Cancer. 7:662019. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zemankova A, Studentova H, Kopova A, Tichy
T, Student V and Melichar B: Neoadjuvant nivolumab and cabozantinib
in advanced renal cell carcinoma in a horseshoe kidney-how to
achieve a safe and radical resection? a case report and review of
the literature. Front Oncol. 13:11159012023. View Article : Google Scholar : PubMed/NCBI
|
